EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Beneficial normalization of cardiac repolarization by carnitine in transgenic short QT syndrome type 1 rabbit models

Ilona Bodi, Lea Mettke iD, Konstantin Michaelides, Tibor Hornyik, Stefan Meier, Saranda Nimani, Stefanie Perez-Feliz, Ibrahim El-Battrawy iD, Heiko Bugger, Manfred Zehender, Michael Brunner iD, Jordi Heijman und 1 weitere

Cardiovascular Research · 2024

DOI: 10.1093/cvr/cvae149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Ilona Bodi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Angiology I, Medical Faculty, Heart Center University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany. Hauptthemen laut MEDLINE: Carnitine, Action Potentials, Disease Models, Animal, Heart Rate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Research Foundation, Netherlands Organization for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Short QT syndrome type 1 (SQT1) is a genetic channelopathy caused by gain-of-function variants in human-ether-a-go-go (HERG) underlying the rapid delayed-rectifier K+ current (IKr), leading to QT-shortening, ventricular arrhythmias, and sudden cardiac death. Data on efficient pharmacotherapy for SQT1 are scarce. In patients with primary carnitine-deficiency, acquired-short QT syndrome (SQTS) has been observed and rescued by carnitine supplementation. Here, we assessed whether carnitine exerts direct beneficial (prolonging) effects on cardiac repolarization in genetic SQTS. Methods and results Adult wild-type (WT) and transgenic SQT1 rabbits (HERG-N588K, gain of IKr) were used. In vivo electrocardiograms (ECGs), ex vivo monophasic action potentials (APs) in Langendorff-perfused hearts, and cellular ventricular APs and ion currents were assessed at baseline and during L-Carnitine/C16-Carnitine-perfusion. Two-dimensional computer simulations were performed to assess re-entry-based ventricular tachycardia-inducibility. L-Carnitine/C16-Carnitine prolonged QT-intervals in WT and SQT1, leading to QT-normalization in SQT1. Similarly, monophasic and cellular AP duration (APD) was prolonged by L-Carnitine/C16-Carnitine in WT and SQT1. As underlying mechanisms, we identified acute effects on the main repolarizing ion currents: IKr-steady, which is pathologically increased in SQT1, was reduced by L-Carnitine/C16-Carnitine and deactivation kinetics were accelerated. Moreover, L-Carnitine/C16-Carnitine decreased IKs-steady and IK1. In silico modelling identified IKr changes as the main factor for L-Carnitine/C16-Carnitine-induced APD-prolongation. 2D simulations revealed increased sustained re-entry-based arrhythmia formation in SQT1 compared to WT, which was decreased to the WT-level when adding carnitine-induced ion current changes.

Conclusion

L-Carnitine/C16-Carnitine prolong/normalize QT and whole-heart/cellular APD in SQT1 rabbits. These beneficial effects are mediated by acute effects on IKr. L-Carnitine may serve as a potential future QT-normalizing, anti-arrhythmic therapy in SQT1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarnitineAction PotentialsDisease Models, AnimalHeart RateAnimals, Genetically ModifiedArrhythmias, CardiacIsolated Heart PreparationERG1 Potassium ChannelAnimalsRabbitsModels, CardiovascularComputer SimulationMyocytes, CardiacTime FactorsPhenotypeElectrocardiographyGenetic Predisposition to DiseaseHumansMaleTachycardia, VentricularMuscular DiseasesHeart Conduction SystemHeart Defects, Congenital

Stichwörter der Autor:innen

Animal modelArrhythmiaCardiac repolarizationCarnitineShort QT syndrome

Substanzen

CarnitineERG1 Potassium ChannelKCNH2 protein, human

Autor:innen und Institutionen

  • Department of Cardiology and Angiology I, Medical Faculty, Heart Center University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.
  • Institute of Experimental Cardiovascular Medicine, Medical Faculty, Heart Center University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.
  • Translational Cardiology, Department of Cardiology, Inselspital, Bern University Hospital, Freiburgstrasse 20, CH-3010 Bern, Switzerland.
  • Translational Cardiology, Department of Physiology, University of Bern, Buehlplatz 5, CH-3012 Bern, Switzerland.
  • Department of Cardiology, Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
  • Department of Cardiology and Angiology, and Institute of Physiology, Ruhr University, Bochum, Germany.

ORCID-Profile: Lea Mettke, Ibrahim El-Battrawy, Michael Brunner, Katja E Odening

Förderung

  • German Research Foundation
  • Netherlands Organization for Scientific Research

Zitieren

APA

Bodi, I., Mettke, L., Michaelides, K., Hornyik, T., Meier, S., Nimani, S., Perez-Feliz, S., El-Battrawy, I., Bugger, H., Zehender, M., Brunner, M., Heijman, J., & Odening, K. E. (2024). Beneficial normalization of cardiac repolarization by carnitine in transgenic short QT syndrome type 1 rabbit models. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae149

Vancouver

Bodi I, Mettke L, Michaelides K, Hornyik T, Meier S, Nimani S, et al. Beneficial normalization of cardiac repolarization by carnitine in transgenic short QT syndrome type 1 rabbit models. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae149

BibTeX
@article{Bodi2024,
  author = {Bodi, Ilona and Mettke, Lea and Michaelides, Konstantin and Hornyik, Tibor and Meier, Stefan and Nimani, Saranda and Perez-Feliz, Stefanie and El-Battrawy, Ibrahim and Bugger, Heiko and Zehender, Manfred and Brunner, Michael and Heijman, Jordi and Odening, Katja E},
  title = {Beneficial normalization of cardiac repolarization by carnitine in transgenic short QT syndrome type 1 rabbit models},
  journal = {Cardiovascular Research},
  year = {2024},
  doi = {10.1093/cvr/cvae149}
}
Kostenlos starten →